Abstract 58P
Background
Non-small cell lung cancer (NSCLC) accounts for 5.9% of all cancers in India and is responsible for 8.1% of all cancer-related mortality. The National Comprehensive Cancer Network (NCCN) reports that 5-year survival rates for NSCLC vary widely, from 15% to 62.5%, depending on specific biomarkers. Therefore, biomarker testing is crucial to guide treatment selection and improve outcomes for patients with NSCLC.
Methods
A total of 108 NSCLC cases were studied, including 66 males and 42 females. Next-generation sequencing (NGS) using a 50-gene panel was performed for all cases. Additionally, fluorescence in situ hybridization (FISH) tests were conducted for ALK, ROS1, and MET genes, and immunohistochemistry (IHC) was used to assess PD-L1 status.
Results
The overall age range of patients was 26-84 years, with the majority aged 55-65. NGS results were obtained for 55 cases. EGFR mutations were identified in 20 patients (10 males and 10 females), with exon 19 deletion being the most common mutation (13 patients). TP53 mutations were found in 16 patients, with 5 having only TP53 mutations and the rest having concurrent driver gene mutations. KRAS mutations were found in 9 patients (4 males and 5 females) with 3 of these having another gene mutation. No mutations were identified in 29 patients. ALK gene rearrangements were present in 2 cases, ROS1 rearrangements in 2 cases, and MET gene amplification in 1 patient. PD-L1 was positive in 19 cases, with >50% expression in 4 cases. Among these 4, one had a RET mutation, and another had ERBB2 gene duplication. Importantly, eight cases had mutations in three or more genes, indicating that concurrent genetic alterations are common.
Conclusions
This study highlights the importance of comprehensive molecular profiling in NSCLC, revealing multiple gene alterations within individual patients. A variety of actionable and non-actionable mutations were identified, underscoring the genomic complexity of NSCLC. These findings emphasize the need for further research to understand the impact of multiple concurrent mutations on disease progression and treatment response, and to develop targeted therapies for these unique genetic profiles.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Oncquest Laboratories Limited.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
61P - Unveiling the distinctive molecular, clinical, and prognostic features of infant acute myeloid leukemia: An analysis study of pediatric AML datasets from the Children's Oncology Group
Presenter: YU TAO
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Evaluating gene alterations associated with recurrence in oral cavity squamous cell carcinoma
Presenter: Amanda Reyes
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Multiplex immunofluorescence analysis of LRRC15 and the TME in early-stage lung adenocarcinoma
Presenter: Jessie Woon
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Molecular profile of triple-negative breast cancer tumours and their association with response to neoadjuvant treatment: A study using next generation sequencing
Presenter: Juan Ramón Berenguer-Marí
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Multi-institutional evaluation of interrater agreement of biomarker-drug pair rankings based on the ESMO scale for clinical actionability of molecular targets (ESCAT) and sources of discordance
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - ESR1 gene mutation in hormone receptor (HR)-positive metastatic breast cancers: An NGS-based exploratory study on Indian population
Presenter: Siddappa Shanthala
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Next generation sequencing in colorectal cancer: Association of BRAF, KRAS mutations with right sided cancers, mucinous disease, lymphovascular/perineural invasion and microsatellite instability
Presenter: Gurpreet Singh Ranger
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Increased expression of interleukin-17 receptor A (IL-17RA) promotes cancer stem-like properties, resistance to 5-fluorouracil, and the expression of ATP-binding cassette transporters in colorectal cancer cells
Presenter: Chih-Yung Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes
Presenter: Margarida Carrolo
Session: Cocktail & Poster Display session
Resources:
Abstract